Test of new vaginal microbicide gel show promise for women.
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control; D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000282:Administration, Intravaginal; D000891:Anti-Infective Agents, Local / Q000008:administration & dosage / Q000009:adverse effects*; D044966:Anti-Retroviral Agents / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006678:HIV; D018023:HIV Seronegativity; D006801:Humans; D007194:India; D063065:Organophosphonates / Q000008:administration & dosage / Q000009:adverse effects; D012449:Safety; D000068698:Tenofovir; D016896:Treatment Outcome; D014481:United States; D014622:Vaginal Creams, Foams, and Jellies / Q000008:administration & dosage / Q000009:adverse effects*
D000891:Anti-Infective Agents, Local; D044966:Anti-Retroviral Agents; D063065:Organophosphonates; D014622:Vaginal Creams, Foams, and Jellies; D000068698:Tenofovir; D000225:Adenine